MY155221A - Renal cell carcinoma treatment - Google Patents
Renal cell carcinoma treatmentInfo
- Publication number
- MY155221A MY155221A MYPI20001452A MYPI20001452A MY155221A MY 155221 A MY155221 A MY 155221A MY PI20001452 A MYPI20001452 A MY PI20001452A MY PI20001452 A MYPI20001452 A MY PI20001452A MY 155221 A MY155221 A MY 155221A
- Authority
- MY
- Malaysia
- Prior art keywords
- cell carcinoma
- renal cell
- treatment
- carcinoma treatment
- effective amount
- Prior art date
Links
- 208000006265 Renal cell carcinoma Diseases 0.000 title 1
- -1 E.G. Proteins 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229950000038 interferon alfa Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28835999A | 1999-04-08 | 1999-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY155221A true MY155221A (en) | 2015-09-30 |
Family
ID=23106761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20001452A MY155221A (en) | 1999-04-08 | 2000-04-07 | Renal cell carcinoma treatment |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP1043025B1 (https=) |
| JP (2) | JP3712914B2 (https=) |
| CN (1) | CN1367702A (https=) |
| AR (1) | AR029160A1 (https=) |
| AT (2) | ATE296638T1 (https=) |
| AU (2) | AU777406B2 (https=) |
| BR (1) | BR0009644A (https=) |
| CA (1) | CA2303752A1 (https=) |
| CO (1) | CO5170412A1 (https=) |
| CY (1) | CY1108919T1 (https=) |
| DE (2) | DE60041291D1 (https=) |
| DK (2) | DK1043025T3 (https=) |
| ES (2) | ES2239953T3 (https=) |
| HU (1) | HU230271B1 (https=) |
| MX (1) | MXPA00003401A (https=) |
| MY (1) | MY155221A (https=) |
| NO (1) | NO328983B1 (https=) |
| NZ (1) | NZ514629A (https=) |
| PE (1) | PE20010026A1 (https=) |
| PT (2) | PT1043025E (https=) |
| TW (2) | TWI310314B (https=) |
| WO (1) | WO2000061174A2 (https=) |
| ZA (1) | ZA200108169B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2303752A1 (en) * | 1999-04-08 | 2000-10-08 | Schering Corporation | Renal cell carcinoma treatment |
| CA2648077A1 (en) * | 2006-03-31 | 2007-11-08 | Schering Corporation | Parenteral low dose type 1 interferons for bladder cancer |
| TW200901989A (en) * | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
| US8053430B2 (en) | 2008-10-06 | 2011-11-08 | Haraldsson Boerje | Treatment of renal cell carcinoma |
| ES2891564T3 (es) | 2010-04-01 | 2022-01-28 | Oncorena Ab | Tratamiento mejorado del carcinoma de células renales |
| CN103463623B (zh) * | 2013-09-03 | 2015-09-09 | 长春海伯尔生物技术有限责任公司 | 一种聚乙二醇干扰素注射液及其制备方法 |
| BR112019024556A2 (pt) | 2017-05-24 | 2020-06-23 | Novartis Ag | Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer |
| WO2024186735A1 (en) * | 2023-03-03 | 2024-09-12 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766582A (en) * | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| WO1999048535A1 (en) * | 1998-03-26 | 1999-09-30 | Schering Corporation | Formulations for protection of peg-interferon alpha conjugates |
| CA2303752A1 (en) * | 1999-04-08 | 2000-10-08 | Schering Corporation | Renal cell carcinoma treatment |
-
2000
- 2000-04-06 CA CA002303752A patent/CA2303752A1/en not_active Abandoned
- 2000-04-06 CN CN00808740A patent/CN1367702A/zh active Pending
- 2000-04-06 AR ARP000101572A patent/AR029160A1/es unknown
- 2000-04-06 AU AU42044/00A patent/AU777406B2/en not_active Ceased
- 2000-04-06 DE DE60041291T patent/DE60041291D1/de not_active Expired - Lifetime
- 2000-04-06 CO CO00025239A patent/CO5170412A1/es not_active Application Discontinuation
- 2000-04-06 DK DK00107100T patent/DK1043025T3/da active
- 2000-04-06 JP JP2000105528A patent/JP3712914B2/ja not_active Expired - Fee Related
- 2000-04-06 AT AT00107100T patent/ATE296638T1/de active
- 2000-04-06 EP EP00107100A patent/EP1043025B1/en not_active Expired - Lifetime
- 2000-04-06 HU HU0200781A patent/HU230271B1/hu not_active IP Right Cessation
- 2000-04-06 DK DK05002952T patent/DK1535623T3/da active
- 2000-04-06 AT AT05002952T patent/ATE419002T1/de active
- 2000-04-06 MX MXPA00003401A patent/MXPA00003401A/es active IP Right Grant
- 2000-04-06 TW TW089106326A patent/TWI310314B/zh not_active IP Right Cessation
- 2000-04-06 DE DE60020442T patent/DE60020442T2/de not_active Expired - Lifetime
- 2000-04-06 NZ NZ514629A patent/NZ514629A/xx not_active IP Right Cessation
- 2000-04-06 ES ES00107100T patent/ES2239953T3/es not_active Expired - Lifetime
- 2000-04-06 TW TW094103729A patent/TW200526243A/zh unknown
- 2000-04-06 BR BR0009644-0A patent/BR0009644A/pt not_active Application Discontinuation
- 2000-04-06 EP EP05002952A patent/EP1535623B1/en not_active Expired - Lifetime
- 2000-04-06 WO PCT/US2000/009127 patent/WO2000061174A2/en not_active Ceased
- 2000-04-06 ES ES05002952T patent/ES2319777T3/es not_active Expired - Lifetime
- 2000-04-06 PT PT00107100T patent/PT1043025E/pt unknown
- 2000-04-06 JP JP2000105531A patent/JP4721488B2/ja not_active Expired - Fee Related
- 2000-04-06 PT PT05002952T patent/PT1535623E/pt unknown
- 2000-04-07 MY MYPI20001452A patent/MY155221A/en unknown
- 2000-04-07 PE PE2000000316A patent/PE20010026A1/es not_active Application Discontinuation
-
2001
- 2001-10-04 ZA ZA200108169A patent/ZA200108169B/en unknown
- 2001-10-05 NO NO20014851A patent/NO328983B1/no not_active IP Right Cessation
-
2004
- 2004-12-23 AU AU2004242454A patent/AU2004242454B2/en not_active Ceased
-
2009
- 2009-03-24 CY CY20091100350T patent/CY1108919T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100321467B1 (https=) | ||
| YU77000A (sh) | Primena peg-ifn-alfa i ribavirina za lečenje hroničnog hepatitisa c | |
| ZA988466B (en) | Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | |
| HUP0100092A3 (en) | Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
| MY155221A (en) | Renal cell carcinoma treatment | |
| TR200101085T2 (tr) | Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi | |
| AU9157901A (en) | Methods of treating inflammatory and immune reactions and compositions therefor | |
| WO2005027936A3 (en) | Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans | |
| WO2000004863A3 (en) | Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions | |
| DK0980205T3 (da) | Anvendelse af en kombination af TALL-104 celler med adriamycin eller cisplatin i behandlingen af maligniteter | |
| MY122052A (en) | Method of treating tourette''s syndrome | |
| MY127276A (en) | Cml therapy | |
| DK0862454T3 (da) | CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner | |
| WO2000061175A3 (en) | Use of pegylated interferon alpha in melanoma therapy | |
| Pehamberger | Perspectives of pegylated interferon use in dermatological oncology | |
| WO2000010590A3 (en) | Cancer treatment | |
| FR2791894B1 (fr) | Utilisation d'interferon beta dans le traitement de la tumeur d'ewing | |
| AU8353601A (en) | Treatment of hepatitis c with thymosin, interferon and ribavirin | |
| TR200000728T2 (tr) | Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı. | |
| FI965171L (fi) | Oksatsofosforiinien, esimerkiksi ifosfamidin, enantiomeerien käyttö kasvainten hoidossa sivuvaikutuksien vähentämiseksi | |
| RU99125650A (ru) | Способ лечения хронического тонзиллита | |
| AU8716001A (en) | Treatment of hepatitis c with thymosin and pegylated interferon | |
| EP1908477A3 (en) | Combination of temozolomide and pegylated interferon-alpha for treating cancer | |
| DK1175224T3 (da) | Pegyleret interferon-alfa i kombination med en CCR5-antagonist til HIV-terapi | |
| HK1035906A (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |